SeaCrest Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

SeaCrest Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$7K	–	628
2019 Q1	$7K	Sell	500 -1,500	-75%	-$13.9K	﹤0.01%	1618
2018 Q4	$6K	Hold	2,000	–	–	﹤0.01%	1637
2018 Q3	$7K	Buy	+2,000	New	+$5.93K	﹤0.01%	1753

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

SeaCrest Wealth Management's AXSM Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Axsome Therapeutics (AXSM) in Q2 2019, closing a stake of 500 shares — an estimated $7K sold.

SeaCrest Wealth Management first reported a position in AXSM in Q3 2018 and held it in 3 quarters. The position peaked at $7K in Q1 2019. 109 funds tracked by Wall St. Rank hold AXSM as of Q2 2019.

SeaCrest Wealth Management reported no remaining Axsome Therapeutics position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 500 Axsome Therapeutics shares in Q2 2019, an estimated $7K.
SeaCrest Wealth Management first reported a position in Axsome Therapeutics in Q3 2018 and held it in 3 quarters.
SeaCrest Wealth Management's Axsome Therapeutics position peaked at $7K in Q1 2019.
109 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.